Tumor recurrence and survival prognosis in patients with advanced gastric cancer after radical resection with radiotherapy and chemotherapy

Table 1 Clinical data of 171 gastric cancer patients

Project	n (%)	Project	n (%)
Age (yr)		T staging
≤ 40	6 (3.5)	T1	8 (4.7)
41-65	126 (73.7)	T2	21 (12.3)
≥ 66	39 (22.8)	T3	86 (50.3)
Gender		T4a	31 (18.1)
Male	124 (72.5)	T4b	25 (14.6)
Female	47 (27.5)	N stages
Surgical hospital		N0	24 (14.0)
Court	102 (59.6)	N1	33 (19.3)
Outer courtyard	69 (40.4)	N2	41 (24.0)
Operation		N3a	58 (33.9)
Subtotal proximal gastrectomy	26 (15.2)	N3b	15 (8.8)
Subtotal distal gastrectomy	76 (44.4)	Clinical stages
Total gastrectomy	58 (33.9)	IB	4 (2.3)
Gastrectomy and other organ	11 (6.5)	IIA	30 (17.5)
Primary lesion site		IIB	23 (13.5)
1/3 upper stomach	37 (21.6)	IIIA	42 (24.6)
1/3 stomach	76 (44.4)	IIIB	45 (26.3)
1/3 subgastric	15 (8.8)	IIIC	27 (15.8)
Whole stomach	15 (8.8)	Lymphatic invasion
Pathological type		Negative	82 (48.0)
Medium to high differentiation	58 (33.9)	Positive	89 (52.0)
Poorly differentiated	91 (53.2)	Peripheral nerve invasion
Mucinous adenocarcinoma	9 (5.3)	Negative	91 (53.2)
Signet-ring cell carcinoma	12 (7.0)	Positive	80 (46.8)
Neuroendocrine degeneration	1 (0.6)	Synchronous chemotherapy
Lauren typing		Capecitabine	95 (55.6)
Intestinal	69 (40.4)	Tegafur	25 (14.6)
Diffuse	95 (55.5)	Other	51 (29.8)
Mixed unclassified	7 (4.1)	Adjuvant chemotherapy regimen
Number of lymph nodes cleaned		XELOX	81 (47.4)
< 15	57 (33.3)	SOX	29 (17.0)
≥ 15	114 (66.7)	FOLFOX	15 (8.8)
Positive lymph nodes		EOF	14 (8.2)
LNR ≤ 0.3	89 (52.0)	FLOT	5 (2.9)
0.3 < LNR ≤ 0.7	58 (33.9)	other	27 (15.7)
LNR > 0.7	24 (14.1)
Age [yr, median (range)]			60 (27-76)
Number of lymph nodes cleaned [n, median (Range)]			19 (5-56)
Number of positive lymph nodes [n, median (Range)]			5 (0-47)

LNR: Lymph node metastasis rate.